In-phantom and in-vivo three dimensional conformal radiation therapy (3DCRT) and 
| INTRODUCTION
Skin injury is a known consequence of breast external radiotherapy treatments. These effects occur particularly in areas subjected to friction such as axilla and skin folds. 1, 2 The severity of these radiation-induced side effects depends on several factors such as radiotherapy treatment modality and planning details; for instance fractionation, total dose, use of bolus, field modifiers, site, concurrent chemotherapy, and the use of biological agents. [1] [2] [3] [4] [5] [6] [7] Skin reactions become more evident toward the end of the treatment with their highest severity generally occurring in the first 2 weeks after the end of the treatment. [1] [2] [3] [4] 8 The skin is generally considered an organ at risk and the mini-and, on the other hand, required doses should be high enough to avoid tumor recurrence. 3, 4, 6, [10] [11] [12] Dose prescription and dosimetry assessment in the skin is not a straightforward task due to the limitation of treatment planning system (TPS) when calculating dose at the surface and at different structures of the skin (basal and dermal layers), as depth and location vary between patients and even in the same patient. 
2.B | MOSFET measurement system characterization methodology
A thorough characterization of the MOSFET-based dosimetry system was performed regarding linearity, reproducibility, and angular dependence for two photon energies commonly used in radiotherapy treatments of the breast (4 and 6 MV). All measurements, with the exception of the angular dependence, were performed using the standard setup above described for the calibration. The angular dependence was performed using a spherical phantom of 14 cm in diameter (Lucy 3D QA phantom -Standard Imaging, Middleton, USA) acquiring measurements with several beam incidences (45 degree increments; Fig. 2 ).
F I G . 1. System calibration setup. The ionization chamber positioned at a depth of 5 cm and the MOSFET detectors at Z max depth for the specific energy.
Angular dependence measurement setup, with Lucy 3D quality assurance phantom.
To assess the variation of the dosimeters response with dose, three MOSFET located at the build-up position of each energy were irradiated in the range of 10 to 350 cGy with SSD = 100 cm. As a control measure (cross calibration), in the same procedure dose measurements were performed using the ionization chamber positioned at a 5 cm depth.
To assess the angular dependence, a MOSFET was placed in the center of the spherical phantom at the isocenter and a series of measurements was carried out by varying the rotation angle of the gantry. The MOSFET was positioned so that its flat side was facing the beam, with the gantry in the 0°position. The gantry angle varied between 0 and 315°in 45°increments.
2.C | In-phantom measurements methodology
The in-phantom measurements were performed using an anthropomorphic female RANDO phantom without breasts to simulate a postmastectomy patient. A CT scan of the phantom was acquired and four measurement points were selected on the phantom surface as seen in The clinical importance of measuring dose in this area is due to the relative high probability of future relapse. [6] [7] [8] [9] The fourth point (P 4 ) was referenced on the axillar area, corresponding to the beam axis projection in the surface. The maximum sensitivity points of the MOSFET detectors were accurately placed on points P 1 -P 4 and measurements were performed with and without bolus.
The output from the TPS calculation on these points was later compared with the MOSFET measured doses. For this purpose, we used the TPS version 13.5 Eclipse ® Varian (Varian Medical Systems, Inc., Palo Alto, CA, USA) using the Anisotropic Analytical Algorithm (AAA) with a calculation grid of 2.5 mm. 3DCRT treatment plans were performed in the RANDO phantom for the breast area, using two oblique opposing tangential fields in field-in field technique with 4 MV photon beams. The VMAT plans were performed with 6 MV using two partial arcs, in the right side from 60°to 181°and in the left side from 340°to 179°.
A 3DCRT and a VMAT plan similar to a clinical case using 4 and 6 MV, respectively, was performed, with and without a bolus (SuperFlab, Eckert & Ziegler, 1 cm thick) for surface dose enhancement.
The prescription was 2 Gy (average dose in the PTV) per fraction for a total dose of 50 Gy in 25 fractions. In the TPS, the bolus was added, based on previous acquires CT unit calibration and no extra CT was performed to the patient.
2.D | In-vivo measurements methodology
After characterization and dose measurements on the skin of the A VMAT technique was performed with 6 MV using two partial arcs.
Bolus (1 cm) was used to increase the skin dose in the last 10 fractions of the 25 fractions in both techniques.
For each patient, the MOSFET detectors were positioned on the respective tattoos and properly secured with adhesive tape [Fig. 4(b) ].
The 
3.A.2 | Angular dependence
The results are presented in the Fig. 6 , for both studied energies.
The standard deviations (%σ) obtained from all the considered directions were 1.86% and 1.67%, for 4 and 6 MV respectively, which are comparable within the ±2% variation over 360°as stated by the manufacturer.
3.B | Phantom dose measurement
The results of the 3DCRT and VMAT plan irradiation of the female anthropomorphic phantom (D M ) were compared with TPS calculated values (D TPS ) with and without bolus.
In Fig. 7 one can observe the difference between measured vs.
calculated values as well as with vs. without bolus for both VMAT and 3DCRT.
As expected, partially due to the lower beam energy used, the | 67 accepted value for the imprecision of dose calculation recommended by the AAPM (20% in the buildup region). 38 
4.B | Patient doses
In both VMAT and 3DCRT techniques, it is also evident from
Figs. 8(a) and 8(b) that, as expected, the skin dose with bolus is superior to the skin dose without bolus. The obtained doses in all the points, except on P 1 , are consistent with the expected results.
This might be due to the fact that, for patients, several different plans were used and the observed measured values are an average of several different geometries. Additionally, the effect of bolus is more evident in the VMAT than in the 3DCRT.
Comparing the skin dose at different points, at P 1 , anatomical upper inner quadrant of the contralateral breast, on average, the measured dose was lower than the dose calculated by the TPS for the 4 MV energy with the 3DCRT technique. This fact implies an overestimating of the dose in the P 1 . However, for the VMAT technique (6 MV) the TPS underestimates the dose at this point with an average difference of 22.8% in patients. At P 2 and P 3 the average measured doses agree with TPS calculation (<4%). In general, P 4 is located in an area that presents large differences for both techniques (<10%).
Similar to the in-phantom experiments, no correction factors were applied to the in-vivo measurements. The same disparity trend between the measured and calculated values by the TPS was verified, compared to the results obtained in the phantom. Based on the analysis of the surface dose at the measurements points, it was verified that the points P 1 and P 4 , corresponding to the anatomical upper inner quadrant of the contralateral breast and to the axillary area, present higher variability values, between calculated and measured, for the two treatment modalities, 3DCRT and VMAT. Since these points are located outside the area directly covered by the treatment fields, they are high dose gradient zones where the calculation is more imprecise. These are also subject to uncertainties of patient positioning and movement. In both techniques, the points on the PTV (P 2 and P 3 ), present higher homogeneity between calculated and measured doses. However, comparing the two treatment techniques, it was found that in the VMAT the TPS tends to underestimate the dose for these two points, contrary to the 3DCRT that the bolus thickness in the cases where an increase or a decrease of surface dose is desirable.
| CONCLUSIONS
From the measurements made in the female anthropomorphic phantom RANDO, considering the treatment plan performed in the TPS, and without any correction factors, there was some discrepancy between the measured and the calculated values by the TPS, with more evidence for plan without bolus. However, this difference was within the ±20% error range, the value referred in the AAPM-TG 53
for the TPS calculation imprecision in the buildup region. These measurements also demonstrate that the surface dose increased in the presence of the bolus when considering VMAT and 3DCRT. This increased surface dose is clearly higher in the VMAT technique. Since the treatment plan is very similar to that performed for treatment of patients with breast carcinoma, measurements using the RANDO phantom seem to indicate an easy and straightforward method of verifying surface dose (in-vivo) applicable in actual clinical situations.
It should be noted that this method may be used in patients with other pathologies, always taking into account the associated error.
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